Home > Specialties > Molecular Microarrays, Mutation/Polymorphism, Gene CYP2D6/CYP2C19

Molecular Microarrays, Mutation/Polymorphism, Gene CYP2D6/CYP2C19

Definition : Polymorphism detection microarrays designed to detect genetic variations in the genes 2D6 and 2C19 of the Cytochrome P450 pathway when used with a molecular assay analyzer. These microarrays can typically detect 29 known polymorphisms in the CYP2D6 gene, including gene duplication and deletion, resulting in the identification of 33 unique alleles; they can also permit the detection of two major polymorphisms in gene CYP2C19. These tests are used to characterize the patient phenotype, permitting a classification of the patient metabolic characteristics (e.g., poor, intermediate, extensive, or rapid metabolizers).

Entry Terms : "Molecular Arrays, Mutation/Polymorphism, Gene CYP2D6/CYP2C19" , "Gene CYP2C19 Polymorphism Microarrays" , "Cytochrome P450 Gene Polymorphism Microarrays" , "Gene CYP2D6 Polymorphism Microarrays" , "Metabolic Phenotype Determination Microarrays"

UMDC code : 20820

   

1-8 of 8 Match(es).

Affymetrix China

Affymetrix China

Affymetrix Inc

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 25,000 peer-reviewed papers have been published using the technology.

Affymetrix Japan KK

Affymetrix Japan KK

Affymetrix Singapore Pte Ltd

Affymetrix Singapore Pte Ltd

Affymetrix UK Ltd

Affymetrix UK Ltd

Luminex Corp

Luminex Corporation (NASDAQ: LMNX) was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the diagnostic and life science industries.

Roche Diagnostics Corp

We are committed to innovating health information with products and services that help our customers improve the lives of their patients

Roche Molecular Systems Inc

Roche Molecular Diagnostics (RMD) is a business area of Roche Diagnostics (Basel, Switzerland) that develops, manufactures and supplies a wide array of innovative medical diagnostic products, services, tests, platforms and technologies. With its broad portfolio of oncology, virology, microbiology and blood screening tests, RMD's clients include researchers, physicians, patients, hospitals, laboratories and blood banks around the world.

1-8 of 8 Match(es).